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Sleep EEG slow-wave activity in medicated and
unmedicated children and adolescents with
attention-deﬁcit/hyperactivity disorder
Melanie Furrer1,2, Valeria Jaramillo1,2, Carina Volk1,2, Maya Ringli1, Robert Aellen1, Flavia M. Wehrle1,2, Fiona Pugin1,
Salome Kurth3, Daniel Brandeis4,5,6, Markus Schmid1, Oskar G. Jenni1,2,6 and Reto Huber 1,2,4
Abstract
Slow waves (1–4.5 Hz) are the most characteristic oscillations of deep non-rapid eye movement sleep. The EEG power
in this frequency range (slow-wave activity, SWA) parallels changes in cortical connectivity (i.e., synaptic density) during
development. In patients with attention-deﬁcit/hyperactivity disorder (ADHD), prefrontal cortical development was
shown to be delayed and global gray matter volumes to be smaller compared to healthy controls. Using data of
all-night recordings assessed with high-density sleep EEG of 50 children and adolescents with ADHD (mean age: 12.2
years, range: 8–16 years, 13 female) and 86 age- and sex-matched healthy controls (mean age: 12.2 years, range: 8–16
years, 23 female), we investigated if ADHD patients differ in the level of SWA. Furthermore, we examined the effect of
stimulant medication. ADHD patients showed a reduction in SWA across the whole brain (−20.5%) compared to
healthy controls. A subgroup analysis revealed that this decrease was not signiﬁcant in patients who were taking
stimulant medication on a regular basis at the time of their participation in the study. Assuming that SWA directly
reﬂects synaptic density, the present ﬁndings are in line with previous data of neuroimaging studies showing smaller
gray matter volumes in ADHD patients and its normalization with stimulant medication.
Introduction
Despite attention-deﬁcit/hyperactivity disorder (ADHD)
is one of the most studied developmental disorders from
child- to adulthood, the genetic and neuronal factors
underlying the development of ADHD are not fully
understood1. Yet, a wide range of neuroimaging studies
revealed that lower gray matter volumes in different brain
regions, e.g. the basal ganglia2,3, and lower cortical thick-
ness4,5 are associated with the disorder. According to
longitudinal magnetic resonance imaging (MRI) data,
there is evidence that a delay in brain maturation underlies
these differences5–8.
In recent years, a new imaging modality proved useful in
tracking brain maturation in humans, i.e. high-density
electroencephalography (hd EEG) recordings during
sleep9. Using this technique, studying sleep EEG slow
waves, oscillations of about 1–4.5 Hz characterizing deep
non-rapid eye movement (NREM) sleep, offer a promising
readout of the functional output of neuronal con-
nectivity10,11. Slow-wave activity (SWA) is deﬁned as the
EEG power in the slow wave frequency band. During the
ﬁrst two decades of life, SWA follows an inverted
U-shaped curve10,12, similar to gray matter development.
Moreover, the predominant location of SWA undergoes a
posterior–anterior shift across the scalp from early
childhood to late adolescence13, which again parallels
cortical maturation14,15. In children with ADHD, SWA
was shown to be relatively increased over central brain
regions16. Since this pattern resembles that of healthy
children of younger age, it supports the assumption that
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ADHD is characterized by a delay in cortical maturation.
Apart from this study, little is known about ADHD-
related topographical alterations in SWA during sleep.
In the present study, we included data of all-night
recordings assessed with high spatial resolution sleep hd
EEG of 50 children and adolescents with ADHD and 86
age- and sex- matched healthy controls. Our aim was to
investigate whether ADHD patients differ from healthy
controls in terms of sleep SWA across the cortex. Addi-
tionally, we aimed to assess the effects of psychostimu-
lants on SWA, because standard prescribed drugs, i.e.
psychostimulants, not only improve speciﬁc and broader
clinical symptoms, but also seem to normalize gray matter
maturation3,17,18.
Methods
Participants
Fifty patients (13 female) between 8 and 16 years (mean:
12.2 years) diagnosed with ADHD (33 combined type, 14
predominantly inattentive type, 3 unknown) were inclu-
ded in the analysis (Table 1). Fifteen were recruited from
the Department for Child and Adolescent Psychiatry at
the University of Zurich (14 diagnosed according to DSM-
IV criteria and 1 according to DSM-V criteria) and 27
from a private children’s practice in Zurich Oerlikon (all
diagnosed according to DSM-IV criteria). For 8 partici-
pants the information about what diagnostic criteria were
applied was not available. Diagnoses were not veriﬁed. All
subjects participated in one of three studies performed
between 2010–2012 (data of 9 participants published in
ref. 16), 2013 (unpublished) and 2017 (unpublished),
respectively. 10 ADHD patients (10–16 years, mean:
12.8 years, 2 female) reported regular intake of stimulant
medication for the treatment of ADHD (methylphenidate,
18–80 mg/day, mean: 42 mg/day) including the morning
of measurement. Another 18 patients (8–16 years, mean:
12.2 years, 5 female) reported regular intake of psychos-
timulants but refrained from medication during the 24 h
before the evening of the night measurement. Sixteen of
them received methylphenidate (Concerta®, Ritalin®,
Ritalin LA®, Medikinet®) with dosages ranging from 10 to
46mg per day (mean: 28 mg/day) and two lisdex-
amphetamine (Elvanse®, both 30mg/day). According to
personal reports, medication was usually taken ﬁve
(workdays) to seven days per week. However, we did not
use a standardized drug diary in the weeks before the
experimental night. Five patients were medicated with
methylphenidate during the time of measurement, but
details on the concentration and last time of drug intake
before the sleep assessment were not assessed. Six
patients (9–14 years, mean: 12.7 years, 1 female) received
psychostimulant medication in the past but had stopped
medical treatment before the start of the study (from
several weeks up to 2 years) and did no longer receive
stimulant drugs, and 11 were drug-naïve (9–15 years,
mean: 11.6 years, 2 female). Details of diagnosis across
these medication subgroups can be found in Table 1.
Eighty-six sex- and age-matched healthy control parti-
cipants (mean age: 12.2 years, range: 8–16 years, 23
female) who were never diagnosed with a psychiatric
disorder were included in the analysis. Matching of the
control group was done as follows: all children in the
same age range as the ADHD patients (8–16 years) were
selected from three studies that were performed in
2008–201313,19,20 and from a study conducted in 2017
(unpublished), resulting in 121 possible healthy control
participants. From this pool, the maximal amount of
participants was chosen such that their age (mean and
standard deviation) as well as the proportion of sexes
precisely matched the ADHD group, leading to a sample
size of n= 86. Recruitment of control participants was
done via local schools, advertisements and social media.
Of note: both, in the patient and control group, subjects
were pooled from several, independent studies. All studies
were performed in the same rooms, with the same equip-
ment (EEG-system, electrodes etc.), followed the same
general procedure and the experimenters were always
master- or PhD students of the same research group. Fur-
thermore, none of the participants reported to suffer from a
diagnosed sleep disorder at the time of measurement.
To evaluate overall cognitive differences between the
groups, the intelligence quotient (IQ) was estimated from
Table 1 Diagnosis of ADHD patients across medication subgroups.
Med in past
n= 6
Unmed
n= 11
Med day before
n= 18
Med measurement
day n= 10
Med unknown
details
Center diagnosed (CAP/CP/unknown) 1/4/1 8/3/0 1/16/1 5/4/1 0/0/5
Diagnose (DSM-IV/DSM-V/unknown) 5/0/1 10/1/0 17/0/1 9/0/1 0/0/5
Type (combined/inattentive/unknown) 2/4/0 9/1/1 13/5/0 7/2/1 2/2/1
Patients were diagnosed by the Department for Child and Adolescent Psychiatry at the University of Zurich (CAP) or by a private children’s practice in Zurich Oerlikon
(CP) according to DSM-IV or DSM-V criteria. The diagnostic criteria from eight participants were unknown. The resulting diagnosis was either combined type or
predominantly inattentive type. Numbers indicate the number of patients belonging to a certain category. Five medicated ADHD patients were not assigned to a
medication subgroup, because details on the concentration and last time of drug intake before the sleep assessment were not available (Med unknown details).
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either German (short-) versions of the WISC-III or
WISC-IV intelligence test21,22 (59 controls, 27 ADHD
patients) or from the TONI-423 (16 controls). No differ-
ences in IQ were found between the control group and
any of the ADHD subgroups. Within the ADHD sub-
groups, IQ was signiﬁcantly lower in patients who were
medicated in the past as compared to unmedicated
patients (p < 0.01, ANOVA with Tukey-Kramer post hoc
test, Supplementary Table S1). However, because of
missing data in 23 ADHD and 11 control participants,
statistical power is limited. In terms of sex, proportions
were similar across medication subgroups and the control
group (ADHD groups: 17, 18, 28, and 20%; control group:
27% females).
For all participants, written informed consent was
obtained from a parent and/or legal guardian and in
addition from adolescent participants 14 years and older.
All studies were approved by the local ethics committee
(Kantonale Ethikkommission Zürich, Switzerland) and
performed according to the Declaration of Helsinki.
Procedure
During 7 days prior to the sleep assessment, participants
were instructed to stick to a regular sleep–wake rhythm with
deviations of bed and get up times of less than 1 h. Regular
bedtimes were veriﬁed with wrist accelerometry (Actiwatch
Plus, AW4, Cambridge Neurotechnology or GeneActiv
accelerometer, ActivInsight Ltd.) and sleep diaries including
bed and get up times and alcohol/caffeine consumption.
Participants were further asked to restrict their caffeine
consumption to a maximum amount of two servings
per day. Medication was only permitted in patients with
ADHD. Whole-night EEG recordings took place in the sleep
laboratory of the University Children’s Hospital Zurich.
Sleep times were scheduled according to habitual bedtimes.
Recording and preprocessing of EEG data
All-night sleep hd EEG was recorded (Electrical Geo-
desics Sensor Net for long-term monitoring, 128 chan-
nels, Electrical Geodesics Inc., EGI, Eugene, OR, USA). All
electrodes were ﬁlled with an electrolyte gel (electro-gel,
Electro-Cap International). Four additional gold electro-
des (Grass Technologies, West Warwick, RI, USA) were
attached to the chin (EMG) and earlobes. EEG data were
referenced to the vertex and sampled at 500 Hz (ﬁltered
between 0.01 and 200 Hz). Data were ofﬂine bandpass
ﬁltered between 0.5 and 40 Hz and down-sampled to
128 Hz. Sleep was visually scored in 20 s epochs according
to the AASM Manual for scoring sleep24. Artifacts were
rejected based on visual inspection during scoring on a
20 s basis. Additionally, artifacts were removed on a
semiautomatic basis if power exceeded a threshold based
on mean power values in the 0.75–4.5 Hz and 20–30 Hz
bands. On average, 17% of epochs were excluded in the
ADHD group and 14% in the control group. Data of each
participant were then re-referenced to the average value
across all electrode channels excluding the lowest row.
Data analysis
Sleep parameters and data of sleep diaries were com-
pared between the groups using ANCOVA with cofactor
age and Tukey-Kramer post hoc tests. EEG power was
calculated for all channels and for 20 s epochs by means of
a fast Fourier transform routine (Hanning window,
averages of ﬁve 4 s epochs, frequency resolution of
0.25 Hz). EEG channels with poor signals were excluded
and the power value was interpolated using spherical
linear interpolation. The lowest row of electrodes was
excluded for analysis resulting in 109 included channels.
In contrast to our previous study16, the larger sample size
allowed the comparison of absolute SWA values (without
any normalization). Therefore, power values were aver-
aged over the ﬁrst hour of artifact-free NREM sleep
(stages N2 and N3) and 1–4.5 Hz and then logarithmized
to ensure normal distribution of the data (Shapiro-Wilk
tests). Electrode-wise group comparisons were performed
using two-tailed Student’s unpaired t tests and statistical
nonparametric mapping (SnPM), using a supratreshold
cluster analysis25 to control for multiple comparisons.
The subgroup analysis was performed by means of both
electrode-wise and across electrodes ANCOVA with
cofactor age. For pairwise comparisons, Tukey-Kramer
post hoc tests were used because of unequal sample sizes,
but equal within-group variances across the groups (p=
0.91, Barlett test). The alpha level of all statistical tests was
set to 0.05. All analyses were performed with the software
package MATLAB (MathWorks, R2014a/R2017b) and R
i386 (version 3.4.2).
Results
Sleep diary
We compared sleep–wake history and caffeine con-
sumption according to sleep diaries between the following
groups: ADHD patients who had received stimulant
medication in the past but not at the time of their parti-
cipation in the study (“ADHD-med in past”, n= 6),
ADHD patients who had never received stimulant medi-
cation (“ADHD-unmed”, n= 11), ADHD patients who
received psychostimulants on a regular basis but refrained
from taking them during the 24 h prior to the EEG
assessment (“ADHD-med day before”, n= 18), ADHD
patients who received psychostimulants on a regular basis
including the morning of measurement (“ADHD-med
measurement day”, n= 10) and healthy controls (n= 86).
Bed time, get up time and time in bed during the week
before the measurement did not differ between groups.
Furthermore, no differences were observed in mean caf-
feine consumption per day, which was very low for all
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groups (Supplementary Table S1). Because the level of
SWA is dependent on the immediate sleep–wake
history26, we calculated time spent awake and time spent
in bed during the last ~24 h before the measurement.
These parameters were not different between the groups
(Supplementary Table S1).
Sleep parameters
For a comparison of sleep architecture and quality of
the recording night, sleep parameters were calculated
from visually scored sleep. EEG recordings were sig-
niﬁcantly longer in the ADHD group “med-day before” as
compared to the control group, leading to signiﬁcantly
more time spent in bed (31.27 min; p= 0.02) and a longer
sleep duration (48.45 min, p < 0.01). Thus, we expressed
all sleep stages and wake after sleep onset as percentage of
total sleep time or time spent in bed. We found no group
differences neither in the composition of sleep stages, nor
in sleep latency or wake after sleep onset, with the
exception of that the ADHD group “med-day before”
spent signiﬁcantly less time in stage N1 as compared to
the control group (p < 0.05) and that the ADHD group
“med-day of measurement” had a longer sleep latency
than the groups “ADHD-unmed” (p < 0.01), “ADHD-med
day before” (p < 0.01) and healthy controls (p < 0.01).
Sleep quality as represented by sleep efﬁciency was high in
all groups (Supplementary Table S2).
Difference in SWA between ADHD patients and healthy
controls
We focused our analyses of SWA on the ﬁrst hour of
artifact-free NREM sleep (stages N2 and N3) for the fol-
lowing reasons: (1) for some participants EEG data were
only available for the beginning of the night due to EEG-
net removal, (2) the EEG recordings were shorter in
healthy controls, and (3) most consolidated sleep results
in a most stable estimate of sleep pressure at the begin-
ning of the night. To assure that the composition of the
ﬁrst NREM sleep hour is similar between groups, we
compared absolute length, sleep architecture as well as
time awake during this time window and found no dif-
ferences between ADHD and healthy control participants
(Supplementary Table S2).
To investigate local SWA changes, electrode-wise
comparisons of SWA (log10) between ADHD and heal-
thy control participants were performed. SWA of ADHD
patients showed a signiﬁcant decrease of 20.5 ± 0.32%
(mean over electrodes ± SEM) in 101 out of 109 electro-
des compared to healthy controls (p < 0.01, two-sided
Student’s unpaired t test, Fig. 1).
Effect of medication on SWA
To identify possible medication effects on the observed
decrease in SWA, we performed a subgroup analysis with
the medication groups speciﬁed above. Because sub-
groups do not perfectly match in terms of age, which is
known to be negatively correlated with SWA, we included
age as a cofactor in the following analyses. Electrode-wise
analysis of covariance (ANCOVA) with cofactor age
revealed a signiﬁcant effect of group on SWA in each
electrode (Fig. 2a). Due to this consistent difference across
the scalp, we averaged SWA across electrodes for the
following analyses. When performing the same ANCOVA
with these average values, as expected, the overall group
effect was highly signiﬁcant (F= 7.98, p < 0.01). Moreover,
a strong effect of age on SWA was observed (F= 77.7, p <
0.01, Fig. 2b), but there was no signiﬁcant interaction
between group and age (F= 0.06, p= 0.99). Pairwise
comparisons (Tukey-Kramer post hoc tests) showed that
SWA was decreased in both the “ADHD-unmed” group
and the “ADHD-med in past” group as compared to both
the “ADHD-med measurement day” group and the con-
trol group. In addition, the “ADHD-med in past” group
showed signiﬁcantly lower SWA than the “ADHD-med
day before” group (Fig. 2c). Since the level of SWA might
also be inﬂuenced by disturbed sleep during the investi-
gated time window, we performed additional ANCOVAs
with cofactor age to test the effect of group on the com-
position of the ﬁrst NREM sleep hour. We found a sig-
niﬁcant effect of group on the proportion of N1 and wake
(p < 0.05). Pairwise comparisons revealed that the
“ADHD-med in past” group experienced signiﬁcantly
more wake and N1 as compared to the “ADHD-med day
before” group (Supplementary Table S2). The result of
signiﬁcantly lower SWA in the “ADHD-med in past”
group has thus to be interpreted with caution, since it
might result from more fragmented sleep.
Discussion
The main result of this study is that sleep EEG SWA is
reduced across the scalp in children and adolescents with
ADHD compared to healthy controls. Interestingly, we
found that the SWA reduction was mostly driven by
patients without stimulant medication at the time of their
participation in the study. Both of these ﬁndings are in
agreement with the well-established anatomical differ-
ences in ADHD patients. Speciﬁcally, several studies
found that children with ADHD exhibit widespread
reductions in gray matter volume and cortical thick-
ness3,4,27,28. Moreover, psychostimulant medication has
been shown to normalize both gray matter3,18 and cortical
thickness29. This parallelism between sleep SWA and
cortical gray matter might not be surprising given that
several studies have established a direct relationship
between the two10,30.
Our knowledge about how slow waves are generated
supports a close relationship between SWA and gray
matter. Slow waves on the cortical surface reﬂect slow
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oscillations of cortical neurons31. These slow oscillations of
cortical neurons during deep sleep are the result of an
unique alternating activity pattern between active “on”
states and completely silent “off” states. The more neurons
are involved and the more synchronized they display these
“on”/“off” states, the larger the amplitude of the surface
slow wave32. Thus, higher synaptic connectivity and
stronger synaptic connections result in larger and highly
synchronized networks of neurons involved in slow oscil-
lations and in more SWA recorded on the cortical surface.
This relationship might explain why particularly during
development, when major reorganization processes take
place, sleep SWA parallels major maturational changes in
cortical gray matter, i.e. (1) the inverted U-shape time
course during the ﬁrst two decades of life10,12,14,33, (2) the
regional maturation along the posterior-anterior
axis13,15,34,35, and (3) experience-dependent changes in
synaptic plasticity, which are favored by processes of brain
maturation36. These close relationships seem not to be
exclusive for gray matter, but speciﬁc aspects of slow
waves may also relate to the maturation of white matter
microstructure37.
Sleep EEG SWA represents a promising readout of age-
dependent changes in functional neuronal connectivity
and may thus complement the anatomical markers of
brain maturation36. As such, this electrophysiological
readout potentially contributes to the understanding of
why ADHD patients show reduced cortical gray matter
for the following reasons. It was proposed that a delay in
cortical maturation underlies the brain anatomical dif-
ferences7. Indeed, in our previous work published in 2013
by Ringli and coworkers, we concluded, based on the
topographical differences in SWA, that children with
ADHD show a less mature pattern than healthy control
participants. Our novel analysis with a larger study
population, allowing a comparison of absolute SWA,
reveals a global reduction of SWA in patients with
ADHD. This observation does not exclude that additional
local changes are present. The directionality of the rela-
tionship between sleep SWA and a maturational delay is
unknown. In other words, whether decreased SWA sup-
ports a cortical developmental delay, or alternatively
whether a maturational delay results in decreased SWA
remains to be established with longitudinal studies. Two
observations, which both support an active role of SWA
in cortical gray matter maturation, encourage the
exploration in more detail: (1) cortical maturation asses-
sed by SWA precedes gray matter maturation measured
by means of MRI38 and (2) good evidence exists that SWA
plays a critical role in synaptic plasticity39. Thus, reduced
SWA in ADHD patients may actively contribute to the
delay of brain development.
Fig. 1 Comparison of slow-wave activity between ADHD patients and healthy controls. a Topographical representation of SWA (log10 EEG
power 1–4.5 Hz) within the ﬁrst hour of artifact-free NREM sleep (N2 and N3, average over participants) for ADHD patients (n= 50) and healthy
controls (n= 86). Values are color-coded and scaled to maximum (red) and minimum (blue) of the control group. b Distribution of t-values over
the scalp resulting from electrode-wise Student’s unpaired t test comparing the ADHD’s with the control group’s log10 SWA. Signiﬁcant electrodes
(p < 0.05, unpaired Student’s t test) are indicated as white dots. SWA was signiﬁcantly reduced in ADHD patients in 101 electrodes (−20.5%, t=−2.8,
p < 0.01).
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Finally, we would like to discuss major confounders and
potential limitations of the study.
First, the attenuated effect on SWA in the medicated
group may be caused by a withdrawal effect rather than by
medication itself, because participants were asked to
refrain from taking medication on the day of EEG
measurement. This, however, is unlikely because patients
who refrained from taking their medication on the day of
measurement did not signiﬁcantly differ from patients
who continued taking psychostimulants on the day of
measurement. On the other hand, psychostimulants may
have an acute effect on SWA, since only patients who
Fig. 2 ANCOVA testing the effect of group and age on slow-wave activity and pairwise comparisons of groups. a Electrode-wise F-values
resulting from ANCOVA (effect of group on log10 SWA after controlling for age) illustrated on the scalp-model. Groups are: ADHD patients who
received stimulant medication in the past but not during the time of the measurement (“ADHD-med in past”, n= 6), ADHD patients who never
received stimulant medication (“ADHD-unmed”, n= 11), ADHD patients who received psychostimulants on a regular basis but refrained from taking
them during the last 24 h before the evening of the measurement (“ADHD-med day before”, n= 18), ADHD patients who received psychostimulants
on a regular basis including the morning of the measurement (“ADHD-med measurement day”, n= 10) and healthy controls (n= 86). Signiﬁcant
electrodes (p < 0.05) are indicated as white dots. The effect of group on SWA was signiﬁcant across all electrodes (F= 7.98, p < 0.01). b Averaged log10
SWA over all electrodes plotted against age. ANCOVA revealed a signiﬁcant effect of age on SWA (F= 77.7, p < 0.01), and no interaction effect (F=
0.06, p= 0.99). c Pairwise comparisons of groups (Tukey-Kramer post hoc tests). Boxplots show the residuals of log10 SWA with the lower and upper
hinges corresponding to the ﬁrst and third quartiles. The whiskers extend from the hinge to the largest/smallest value at most 1.5 times the inter-
quartile range from the hinge. Lines above boxplots indicate signiﬁcant pairs (p < 0.05). SWA was signiﬁcantly lower in both the “ADHD-med in past”
and the “ADHD-unmed” group compared to both the “ADHD-med measurement day” and the control group. Furthermore, SWA was lower in the
“ADHD-med in past” compared to the “ADHD-med day before” group. Results of the “ADHD-med in past” group have to be taken with caution, since
their sleep during the investigated time window seemed to be more disturbed.
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continued taking their medication on the day of EEG
assessment, but not those who withdrew from it, differed
signiﬁcantly from unmedicated patients. Additionally, in
agreement with previous studies40,41, we observed an
acute medication effect on sleep onset latency (Supple-
mentary Table S2), supposedly due to the arousal-
enhancing effects of psychostimulants. Thus, based on
our data we cannot conclude if the main effect of sti-
mulant medication is mediated by a long-term or an
immediate effect.
Second, symptom severity could mediate some of the
group differences we observe. Unfortunately, across the
extended time window in which measurements were
taking place, no standard procedures for the assessment
of symptom severity was conducted. Consistent across all
patients is that they had a diagnosed ADHD and fulﬁlled
the same exclusion and inclusion criteria. However, our
data do not allow to explore the relationship between
present ﬁndings and symptom severity. Furthermore, the
proportion of children recruited by one or the other
institution varies across medication subgroups. While the
majority of unmedicated patients was recruited by one
institution, most medicated patients who refrained from
medication intake on the day of measurement were
recruited by the other (Table 1).
Third, the level of SWA depends on experiences and
activities performed during the day36,42,43. Therefore, it is
possible that alterations in SWA are not only a result of
different brain anatomy between children with and
without ADHD, but also of differing daytime activities. To
account for differences in time awake prior to the EEG
assessment and potential effects on SWA26, we incorpo-
rated the evaluation of sleep diaries, which showed that
sleep–wake history did not differ between ADHD and
control participants. It is thus very unlikely that the
decrease in SWA was caused by lower sleep pressure in
ADHD patients.
Fourth, one might speculate that global SWA changes
in ADHD patients result from disturbed sleep in this
patient group. By looking at the architecture of the ﬁrst
NREM sleep hour we could show that durations of wake
and sleep stage N1 did not differ between ADHD and
control subjects. A more direct measure for sleep frag-
mentation is the number of awakenings. Thus, we com-
pared awakening counts during the ﬁrst NREM sleep hour
of ADHD patients (n= 50) with those of healthy controls
(n= 86) and found that ADHD patients tended to wake
up even fewer times than healthy controls (p= 0.04).
When performing a medication-subgroup analysis, we
counted signiﬁcantly more awakenings for the ADHD
group “med in past” as compared to the ADHD group
“med day before” (p= 0.04, Tukey-Kramer post hoc test),
which is consistent with different durations of wake and
N1 in the same subgroups (see above). Thus, apart from
the “ADHD-med in past” group, decreased SWA in
ADHD patients cannot be explained by more sleep
fragmentation.
Fifth, undetected sleep problems in the ADHD group
might have inﬂuenced our results. Sleep disorders, such as
obstructive sleep apnea and periodic limb movements,
were shown to affect a high percentage of ADHD
patients44. In the present study, we excluded patients who
reported to suffer from sleep problems and/or a diag-
nosed sleep disorder, but did not perform a poly-
somnography allowing a clinical assessment of the
participant’s sleep. It is, however, unlikely that the ADHD
group differed from the control group in terms of sleep
problems, since we did not detect differences in the
amount of awakenings, the length of wake after sleep
onset, nor in sleep–wake history.
Finally, also power in other frequency ranges may show
differences between ADHD and control participants.
Relatedly, recent studies also reported lower EEG power
in the sigma-frequency range (12–16 Hz) in children with
ADHD45,46, however, without focusing on topographical
differences. We limited our hypothesis driven approach to
the SWA frequency range to avoid a reduction in statis-
tical power because of multiple comparisons.
Having these limitations in mind, our results show that
children and adolescents diagnosed with ADHD experi-
ence a reduction in EEG SWA during NREM sleep. Sti-
mulant medication seems to have normalizing effects on
SWA. These ﬁndings are in line with neuroimaging stu-
dies showing decreased levels of gray matter, possibly
caused by a maturational delay in ADHD patients. This
parallelism between ADHD-related gray matter changes
and SWA changes needs to be further investigated by
assessing both MRI and sleep EEG in a large patient
sample.
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